KR20090067809A - Solid preparation for dialysis and preparation method thereof - Google Patents
Solid preparation for dialysis and preparation method thereof Download PDFInfo
- Publication number
- KR20090067809A KR20090067809A KR1020070135594A KR20070135594A KR20090067809A KR 20090067809 A KR20090067809 A KR 20090067809A KR 1020070135594 A KR1020070135594 A KR 1020070135594A KR 20070135594 A KR20070135594 A KR 20070135594A KR 20090067809 A KR20090067809 A KR 20090067809A
- Authority
- KR
- South Korea
- Prior art keywords
- dialysis
- solid preparation
- glucose
- spray dried
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 56
- 239000007787 solid Substances 0.000 title claims abstract description 42
- 238000000502 dialysis Methods 0.000 title claims abstract description 40
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 49
- 239000008103 glucose Substances 0.000 claims abstract description 49
- 239000008187 granular material Substances 0.000 claims abstract description 34
- 239000003792 electrolyte Substances 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 26
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000007921 spray Substances 0.000 claims description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 43
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 38
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 32
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 239000011230 binding agent Substances 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 235000002639 sodium chloride Nutrition 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 19
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 18
- 239000001110 calcium chloride Substances 0.000 claims description 18
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 16
- 239000001103 potassium chloride Substances 0.000 claims description 15
- 235000011164 potassium chloride Nutrition 0.000 claims description 15
- 238000005507 spraying Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 13
- 239000001632 sodium acetate Substances 0.000 claims description 13
- 235000017281 sodium acetate Nutrition 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 239000008151 electrolyte solution Substances 0.000 claims description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 235000011148 calcium chloride Nutrition 0.000 claims description 6
- 235000011147 magnesium chloride Nutrition 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 19
- 239000002904 solvent Substances 0.000 abstract description 5
- 239000000385 dialysis solution Substances 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 32
- 229960000583 acetic acid Drugs 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- ZLMJMSJWJFRBEC-AKLPVKDBSA-N potassium-42 Chemical compound [42K] ZLMJMSJWJFRBEC-AKLPVKDBSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000005029 sieve analysis Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
Abstract
본 발명은 투석용 고형 제제의 제조 방법, 및 상기 제조 방법으로 제조되며 a) 전해질 및 b) pH 조정제를 포함하고, 추가로 c) 포도당을 포함할 수 있는 투석용 고형 제제에 관한 것이다. 본 발명의 투석용 고형 제제는 기존의 투석용제 분말 또는 과립과 달리 용해속도가 높고 흡습도가 낮아 투석액을 빠르고도 손쉽게 준비할 수 있도록 하며, 함량 균일성이 높아 투석액 제조시 균일한 함량을 갖는 투석액의 제공이 가능하다는 장점이 있다. The present invention relates to a process for the preparation of a solid preparation for dialysis, and to a solid preparation for dialysis, which is prepared by the preparation method and which comprises a) an electrolyte and b) a pH adjusting agent, and which may further comprise c) glucose. The solid preparation for dialysis of the present invention, unlike conventional dialysis solvent powder or granules, has a high dissolution rate and low hygroscopicity so that the dialysis solution can be prepared quickly and easily. There is an advantage that can be provided.
Description
본 발명은 투석용 고형 제제의 제조 방법, 및 상기 제조 방법으로 제조되며 a) 전해질 및 b) pH 조정제를 포함하고, 추가로 c) 포도당을 포함할 수 있는 투석용 고형 제제에 관한 것이다.The present invention relates to a process for the preparation of a solid preparation for dialysis, and to a solid preparation for dialysis, which is prepared by the preparation method and which comprises a) an electrolyte and b) a pH adjusting agent, and which may further comprise c) glucose.
투석 요법(Dialysis therapy)은 신부전 환자의 혈액 내 노폐물 제거와 전해질 조절을 목적으로 하며, 이때 사용되는 투석액은 여러 종류의 전해질과 pH 조정제 등을 함유하는 제제와 탄산수소나트륨을 주사용수에 희석시켜 제조된다. Dialysis therapy is aimed at removing wastes in the blood of renal failure patients and controlling electrolytes.The dialysis solution used here is prepared by diluting a solution containing various electrolytes and pH adjusting agents and sodium bicarbonate in water for injection. do.
상기한 여러 종류의 전해질을 함유하는 제제는, 통상적으로, 염화나트륨, 염화칼륨, 염화칼슘, 염화마그네슘 및 아세트산나트륨 등의 전해질 중에서 적어도 2종 이상의 전해질을 포함하며, 각 성분의 함량이 균일한 분말을 제조하는 것이 어렵기 때문에 액상(Liquid Phase)으로 제조되지만 보관 용이성 등을 고려하면 분말 형태의 고형(Solid Phase) 제제로 제조되는 것이 바람직하다. Formulations containing the various types of electrolytes described above typically contain at least two or more electrolytes from among electrolytes such as sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate, and produce a powder having a uniform content of each component. Since it is difficult to prepare in a liquid phase (Liquid Phase), but in consideration of the ease of storage, it is preferable to be prepared in a solid (Solid Phase) formulation in the form of a powder.
이에 따라, 일본국 특개 제1994-335528호, 및 일본국 특개 제1990-311418호에서는 건식 조립 장치 내에서 염화나트륨, 염화칼륨, 염화칼슘, 염화마그네슘 및 아세트산나트륨의 전해질 성분을 혼합, 압축, 분쇄하고 조립한 후 다시 분쇄하여 과립을 제조하는 방법을 개시하고 있으며, 일본국 특개 2004-121822호에서는 분쇄한 전해질 성분에 포도당이나 염화칼슘을 녹인 액을 분무하여 과립화하는 방법을 개시하고 있다. 그러나, 압축과 분쇄 시 장치의 마모 등에 의한 이물 혼입이 일어날 수 있는 단점이 있으며, 염화칼슘이나 염화마그네슘과 같은 성분들은 조해성(deliquescence)이 있어 균일하게 혼합되기 어려운 점이 있으므로, 함량이 균일한 과립을 얻기 어려워, 분쇄 후 상기 분쇄물을 혼합할 수 있는 별도의 특수한 혼합 설비에서 혼합공정을 거쳐야만, 분쇄한 전해질의 함량 균일성을 달성할 수 있으므로, 전체적인 제조공정이 길어지고 복잡해진다는 문제점이 있다. 게다가, 상기와 같이 제조되는 종래의 고형 제제는 흡습성이 높아 장기 보존 시 굳거나 응집에 의한 괴상물을 형성시켜 용해 속도가 현저히 저하되는 현상이 나타난다. Accordingly, Japanese Patent Application Laid-Open No. 1994-335528 and Japanese Patent Application Laid-Open No. 1990-311418 include mixing, compressing, grinding and assembling the electrolyte components of sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate in a dry granulation apparatus. Later, a method of producing granules by pulverization is disclosed, and Japanese Patent Laid-Open No. 2004-121822 discloses a method of granulating by spraying a solution of glucose or calcium chloride dissolved in a pulverized electrolyte component. However, there is a disadvantage in that foreign matter may be mixed due to wear of the device during compression and grinding, and components such as calcium chloride and magnesium chloride have deliquequescence and are difficult to be uniformly mixed, thereby obtaining granules having a uniform content. It is difficult to achieve uniformity of the content of the pulverized electrolyte only through a mixing process in a separate special mixing facility that can mix the pulverized product after pulverization, and thus there is a problem that the overall manufacturing process becomes long and complicated. In addition, the conventional solid preparations prepared as described above have a high hygroscopicity and exhibit a phenomenon that the dissolution rate is remarkably lowered by forming solids due to aggregation or aggregation during long-term storage.
또한, 일본국 특개 제1999-343230호, 일본국 특개 제2000-26280호, 일본국 특개 제2001-149468호, 및 일본국 특개 제2001-327597호 등에서는 염화나트륨 입자에 다른 전해질을 코팅하는 유동층 조립 방법에 의한 고형 제제의 제조 방법을 개시하고 있고, 일본국 특개 제1994-178802호, 일본국 특개 제1994-40562호에서는 핵 입자를 가지는 이층 구조의 고형 제제 제조방법을 개시하고 있으며, 한국등록특허 제398299호에서는 염화나트륨과 염화칼슘을 핵층으로 하고, 기타 전해질 조성물과 pH조정제를 2층, 그리고 포도당이 3층인 구조로 이루어진 고형 투석제를 개시하고 있다. 하지만, 상기 고형 투석제는 용해 시 핵(seed) 역할을 하는 염화나트륨 입자가, 코팅된 다른 성분과 동시에 녹지 않고 잔존하여 완전히 용해되는데 시간이 지연되므로, 용해 속도가 늘어난다. 따라서 투석액 제조 시 충분히 교반하지 않으면 핵 입자의 용해가 늦어지는 단점이 있고, 또한 전해질 불용입자를 물속에서 육안으로 식별하기 어려워 전해질이 완전히 용해되지 않은 투석액을 환자에게 제공할 수 있는 문제가 있다. 게다가 다른 전해질 수용액을 코팅하는 유동층 조립 방법의 경우에는, 밀도가 낮고, 강도가 작은 조립물이 생성되기 쉬운 문제점이 있으며, 이층 구조의 고형 제제를 제조하는 방법에서는 제조 과정 중 가열 혼합 시에 전해질 간의 끈끈한 성질 때문에, 각 성분이 균일하게 분포되기 곤란하여 함량 불균일이 쉽게 일어나므로, 이를 방지하기 위하여 통상의 교반 장치에 비하여 큰 설비가 필요하게 되어, 이에 따라 특수화, 대형화 된 설비가 필요하다는 단점이 있다. Further, Japanese Laid-Open Patent Publication No. 1999-343230, Japanese Laid-Open Patent Publication No. 2000-26280, Japanese Laid-Open Patent Publication No. 2001-149468, Japanese Laid-Open Patent Publication No. 2001-327597 and the like have a fluidized bed assembly in which sodium chloride particles are coated with another electrolyte. A method for producing a solid formulation by the method is disclosed, and Japanese Patent Application Laid-Open No. 1994-178802 and Japanese Patent Application Laid-Open No. 1994-4562 disclose a method for producing a solid formulation having a bilayer structure having nuclear particles, and registered in Korea. No. 398299 discloses a solid dialysis agent comprising sodium chloride and calcium chloride as nucleus layers, two electrolyte layers and a pH adjuster, and three layers of glucose. However, since the solid dialysis agent is delayed in dissolving sodium chloride particles, which serve as seeds during dissolution, do not dissolve simultaneously with other coated components and remain completely dissolved, the dissolution rate increases. Therefore, there is a problem in that the dissolution of the nuclear particles is slow if not sufficiently stirred during the preparation of the dialysate solution, and it is difficult to visually identify the electrolyte insoluble particles in water, thereby providing a patient with a dialysate solution in which the electrolyte is not completely dissolved. In addition, in the case of a fluidized bed granulation method of coating another electrolyte solution, there is a problem that low density and low strength granules are easily generated, and in the method of preparing a solid preparation having a two-layer structure, between electrolytes during heating and mixing during the manufacturing process Because of the sticky nature, it is difficult to uniformly distribute each component, so that content irregularities easily occur, and thus, a large facility is required to prevent this, and thus, there is a disadvantage that a specialized and large-scale facility is required. .
또한, WO81/00515에서는 분무 건조법을 이용한 분말 투석용 제제를 개시하고 있으나 이는 전해질 성분이 균일하게 분포되도록 개선하고자 한 것일 뿐, 분무 건조물이 지닌 낮은 유동성 또는 용해도 저하의 문제점에 대해서 해결하지 못했다.In addition, WO81 / 00515 discloses a powder dialysis preparation using a spray drying method, which is intended to improve the distribution of electrolyte components uniformly, and does not solve the problem of low fluidity or low solubility of the spray dried material.
상기와 같이, 종래의 제조 방법에 의해 제조된 투석용 고형 제제는 함량 불균일성, 높은 흡습성, 낮은 유동성 및/또는 용해 속도 등의 문제점을 내포하고 있었다.As described above, the solid preparation for dialysis prepared by the conventional manufacturing method has problems such as content unevenness, high hygroscopicity, low flowability and / or dissolution rate.
이에 본 발명자들은 상기의 문제점들을 해결하고자 연구한 결과, 전해질 용액을 분무 건조하여 분무 건조물을 제조한 후, 상기 분무 건조물에 바인더를 분무하여 과립화하는 공정을 통해 높은 함량 균일성, 높은 유동성, 낮은 질량편차 및 낮은 흡습성과 특히 우수한 용해속도를 갖는 과립을 제조하였으며, 상기 과립에 아세트산과 같은pH 조정제를 분사하여 투석용 고형 제제를 제조하였다. Accordingly, the present inventors have studied to solve the above problems, and as a result of spray drying the electrolyte solution to prepare a spray dried product, a high content uniformity, high fluidity, low flow through the process of granulating by spraying a binder on the spray dried material Granules having a mass deviation and low hygroscopicity and a particularly good dissolution rate were prepared, and solid granules for dialysis were prepared by spraying a pH modifier such as acetic acid on the granules.
이로써, 본 발명자들은 상기 제조 방법으로 제조한 투석용 고형 제제가 전술한 문제점을 해결한 것을 확인하여 본 발명을 완성하였다. Thus, the present inventors confirmed that the solid preparation for dialysis prepared by the above production method solved the above-mentioned problems and completed the present invention.
즉, 본 발명은 용해 속도, 각 성분의 함량 분포의 균일성 및 제조 효율을 개선시킨 투석용 고형 제제 및 이의 제조 방법을 제공하는 것을 목적으로 한다.That is, an object of the present invention is to provide a solid preparation for dialysis and a method for producing the same, which have improved dissolution rate, uniformity of content distribution of each component, and production efficiency.
상기 목적을 달성하기 위하여, 본 발명은 전해질 수용액을 제조한 후, 이의 분무건조물을 제조하는 제1 단계; 상기 제1 단계의 분무건조물에 바인더 용액을 분사하여 과립을 제조하는 제2 단계; 및 상기 제2 단계에서 제조된 과립을 건조한 후 조립하고 pH 조정제를 분사하는 제3 단계를 포함하는 것을 특징으로 하는 투석용 고형 제제의 제조 방법을 제공한다.In order to achieve the above object, the present invention after preparing an aqueous electrolyte solution, the first step of preparing a spray dried thereof; A second step of preparing granules by spraying a binder solution on the spray dried material of the first step; And a third step of drying and granulating the granules prepared in the second step and spraying the pH adjuster.
본 발명의 제조 방법에서, 상기 제2 단계를 수행하기 이전에 상기 제1 단계의 분무 건조물에 포도당 분말을 혼합하는 단계를 더 포함할 수 있다. 이러한 경우, 상기 제2 단계에서의 바인더 용액은 제1 단계에서 제조된 분무 건조물과 포도 당의 혼합물에 분사된다. In the manufacturing method of the present invention, prior to performing the second step may further comprise the step of mixing the glucose powder in the spray drying of the first step. In this case, the binder solution in the second step is sprayed onto the mixture of the spray dried product and the glucose prepared in the first step.
본 발명의 제조 방법에서, 상기 분무 건조물은 상기 전해질 수용액을 투입온도(In-Let temp.): 100 ~ 300℃, 방출온도(Out-Let temp.): 100 ~ 200℃, 공기주입속도 600 ~ 1000 l/h의 조건 하에서 분무 건조시켜 제조되는 것을 특징으로 한다.In the production method of the present invention, the spray dried product is the electrolyte solution inlet temperature (In-Let temp.): 100 ~ 300 ℃, Outlet temperature (Out-Let temp.): 100 ~ 200 ℃, air injection rate 600 ~ It is characterized in that it is prepared by spray drying under conditions of 1000 l / h.
본 발명의 전해질 성분은 염화나트륨, 염화칼륨, 염화칼슘, 염화마그네슘, 아세트산나트륨 및 이의 혼합으로 이루어진 군으로부터 선택되는 것을 특징으로 한다.The electrolyte component of the present invention is characterized in that it is selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate and mixtures thereof.
본 발명의 바인더 용액은 물 또는 포도당 수용액, 바람직하게는 0~ 50% 포도당 수용액을 사용하는 것을 특징으로 한다.The binder solution of the present invention is characterized by using water or aqueous glucose solution, preferably 0-50% aqueous glucose solution.
본 발명의 바인더 용액의 첨가량은 상기 분무 건조물 또는 분무 건조물과 포도당 분말의 혼합물의 총중량에 대하여 3~10 중량%, 바람직하게는 5~7 중량%인 것을 특징으로 한다.Addition amount of the binder solution of the present invention is characterized in that 3 to 10% by weight, preferably 5 to 7% by weight relative to the total weight of the spray dried product or the mixture of the spray dried product and the glucose powder.
본 발명의 pH 조정제는 상기 과립의 총중량에 대하여 1.0~4.0 중량%의 함량으로 첨가되는 것을 특징으로 한다. 상기 pH 조정제는 아세트산, 옥살산, 숙신산, 시트르산, 타르타르산, 말레인산을 포함하는 유기산 및 염산을 포함하는 무기산으로 구성되는 군으로부터 선택되는 하나 이상인 것을 특징으로 한다.PH adjuster of the present invention is characterized in that it is added in an amount of 1.0 to 4.0% by weight based on the total weight of the granules. The pH adjuster is characterized in that at least one selected from the group consisting of acetic acid, oxalic acid, succinic acid, citric acid, tartaric acid, an organic acid including maleic acid and an inorganic acid containing hydrochloric acid.
또한, 본 발명은 상기의 제조 방법에 의해서 제조되고, 입도측정기(Matersizer X, Malvern, UK)를 이용하여 플로우 셀(Flow cell)에 투석용 고형 제제를 15g투입한 후, 상기 제제의 입자가 용해하기 시작한 시점부터 제제 입자가 완전히 녹아 사라지는 시간이 110초 이하인 투석용 고형 제제를 제공한다.In addition, the present invention is prepared by the above production method, and after the 15 g of the solid preparation for dialysis in a flow cell (Matersizer X, Malvern, UK) using a particle size analyzer (Matersizer X, Malvern, UK), the particles of the preparation is dissolved A solid preparation for dialysis is provided, wherein the time for starting the preparation particles to completely dissolve and disappear is 110 seconds or less.
또한, 본 발명은 상기의 제조 방법에 의해서 제조되며, a) 전해질 성분 및 b) pH 조정제를 포함하는 투석용 고형 제제를 제공한다.The present invention also provides a solid preparation for dialysis, which is prepared by the above production method and which comprises a) an electrolyte component and b) a pH adjuster.
본 발명의 투석용 고형 제제는 상기의 성분 외에 c) 포도당을 추가로 포함할 수 있는 것을 특징으로 한다.Solid preparation for dialysis of the present invention is characterized in that it may further comprise c) glucose in addition to the above components.
이하에서 본 발명을 구체적으로 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 전해질 수용액을 제조한 후, 이의 분무 건조물을 제조하는 제1 단계; 상기 제1 단계의 분무 건조물에 바인더 용액을 분사하여 과립을 제조하는 제2단계; 및 상기 제2 단계에서 제조된 과립을 건조한 후 조립하고 pH 조정제를 분사하여 혼합하는 제3 단계를 포함하는 것을 특징으로 하는 투석용 고형 제제의 제조 방법을 제공한다.The present invention after preparing an aqueous electrolyte solution, the first step of preparing a spray dried material thereof; A second step of preparing granules by spraying a binder solution on the spray dried material of the first step; And a third step of drying and granulating the granules prepared in the second step and injecting and mixing the pH adjusting agent.
여기서, 상기 제1 단계에서의 전해질 수용액은 염화나트륨, 염화칼륨, 염화칼슘, 염화마그네슘, 아세트산나트륨 및 이의 혼합으로 이루어진 군으로부터 선택되는 전해질 성분을 물 또는 정제수에 용해시키고 30~50℃ 바람직하게는 40℃ 정도로 가열하여 제조된다. 이때, 상기 전해질 성분의 총 중량은 물 또는 정제수의 총 중량에 대하여 2~4 중량%가 사용된다.Here, the electrolyte solution in the first step is an electrolyte component selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium acetate and mixtures thereof in water or purified water and 30 to 50 ℃ preferably 40 ℃ It is prepared by heating. At this time, the total weight of the electrolyte component is used 2 to 4% by weight based on the total weight of water or purified water.
그리고, 상기 분무 건조물은 상기와 같이 제조된 전해질 수용액을 10~15시간, 바람직하게는 12시간 정도 방치한 후, 투입온도(In-Let temp.): 100~300℃, 방출온도(Out-Let temp.): 100~200℃, 공기주입속도 600~1,000 l/h의 조건 하에서 분무 건조하여 제조된다. In addition, the spray dried material is left in the electrolyte solution prepared as described above for 10 to 15 hours, preferably about 12 hours, the input temperature (In-Let temp.): 100 ~ 300 ℃, the discharge temperature (Out-Let temp.): It is prepared by spray drying under conditions of 100 to 200 ° C. and an air injection rate of 600 to 1,000 l / h.
본 발명의 제조 방법에 있어서, 상기 전해질 성분은 그들의 총 혼합 중량에 대하여 염화나트륨, 염화칼륨, 염화칼슘, 염화마그네슘 및 아세트산나트륨이 각각 78.22~ 93.86: 1.26~ 3.65: 1.24~ 3.60: 0.86~ 2.49: 2.77~ 12.04 중량% 배합량으로 혼합되어 사용되는 것이 바람직하다. In the production method of the present invention, the electrolyte components are sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium acetate relative to their total mixed weight, respectively 78.22 ~ 93.86: 1.26 ~ 3.65: 1.24 ~ 3.60: 0.86 ~ 2.49: 2.77 ~ 12.04 It is preferable to mix and use by the weight% compounding quantity.
상기 제1 단계에서 제조된 분무건조물은 20~75 ㎛의 분말입경을 가지는 것이 본 발명에 의하여 최종적으로 제조된 고형투석용제의 용해속도 및 유동성을 높이는 데에 있어서 바람직하다.The spray dried product prepared in the first step preferably has a powder particle diameter of 20 to 75 μm in order to increase the dissolution rate and fluidity of the solid dialysis solvent finally prepared according to the present invention.
한편, 상기와 같이 분무 건조물을 제조한 후 분말 형태의 포도당을 첨가할 수 있으며, 이로써 열에 약한 포도당의, 건조과정으로부터 발생 될 수 있는 변성을 방지할 수 있다. 이때, 상기 포도당은 분무 건조물 및 포도당 혼합물의 총 중량에 대하여 0~20중량%가 되도록 혼합되는 것이 바람직하다. Meanwhile, after preparing the spray dried product as described above, glucose in powder form may be added, thereby preventing degeneration of glucose, which is weak in heat, from the drying process. At this time, the glucose is preferably mixed so as to be 0 to 20% by weight based on the total weight of the spray dried product and the glucose mixture.
이러한 경우, 본 발명에 따른 제2 단계는 분무 건조물과 포도당의 혼합물에 바인더 용액을 분사하고 그 결과물을 건조시켜 과립화하는 습식 조립(wet granulation) 단계로 구성된다. 반면, 상기 제1 단계에서의 분무 건조물에 포도당이 혼합되지 않는 경우, 상기 제2 단계는 분무 건조물에 대해서만 수행된다. In this case, the second step according to the invention consists of a wet granulation step of spraying a binder solution onto the mixture of spray dried and glucose and drying the resultant to granulate. On the other hand, when glucose is not mixed in the spray dry matter in the first step, the second step is performed only on the spray dry matter.
상기 바인더 용액은 미세 분사 노즐을 장착한 공기 분무기(air atomizer)형 노즐을 통해 분사되며, 이때 미립화된 바인더 용액은 전해질 분무 건조물과 포도당 혼합물의 균일한 혼합을 가능하게 해준다. 이와 같이 노즐을 통해 바인더 용액을 분사함으로써 노즐을 사용하지 않는 경우보다 적은 양만으로도 양질의 과립을 형성시키는 것이 가능하며, 이로 인해 건조 시간을 줄일 수 있다. The binder solution is sprayed through an air atomizer-type nozzle equipped with a fine spray nozzle, where the atomized binder solution enables uniform mixing of the electrolyte spray dried product and the glucose mixture. As such, by spraying the binder solution through the nozzle, it is possible to form high quality granules in a smaller amount than when the nozzle is not used, thereby reducing the drying time.
본 발명의 바인더 용액의 첨가량은 상기 분무 건조물 또는 분무 건조물과 포도당 분말의 혼합물의 총 중량에 대하여 3~10 중량%, 바람직하게는 5~ 7중량%인 것을 특징으로 한다.The addition amount of the binder solution of the present invention is characterized in that 3 to 10% by weight, preferably 5 to 7% by weight relative to the total weight of the spray dried product or the mixture of the spray dried product and the glucose powder.
본 발명의 투석용 제제의 제조 시, 바인더 용액으로서 포도당 수용액을 사용하는 경우 결합력이 증가하여 미세조립물의 비율이 낮아지고, 과립의 흐름성이 좋아지며, 용해도에 긍정적인 효과를 준다. 이 경우, 바인더 용액으로 사용하는 포도당 수용액의 농도는 0~50%, 바람직하게는 본 발명의 제제가 포도당을 포함하는 경우에는 35~45% 포도당 수용액인 것 또는 포도당을 포함하지 않는 경우는 0% 인 것을 특징으로 한다. 이는, 포도당 수용액의 농도가 50%를 초과하는 경우, 포도당의 용해시간이 장시간 소요되며, 또한 용해된 포도당 수용액이 제조 중 석출될 가능성이 있기 때문이다.In the preparation of the dialysis preparation of the present invention, when the aqueous glucose solution is used as the binder solution, the binding force is increased, the ratio of the fine granules is lowered, the flowability of the granules is improved, and the solubility is positive. In this case, the concentration of the aqueous glucose solution used as the binder solution is 0 to 50%, preferably 35 to 45% of the aqueous glucose solution when the preparation of the present invention contains glucose or 0% when the glucose solution is not included. It is characterized by that. This is because, when the concentration of the aqueous glucose solution exceeds 50%, the dissolution time of the glucose takes a long time, and there is a possibility that the dissolved aqueous glucose solution is precipitated during production.
상기의 제2 단계에서 제조된 과립의 건조 온도는 30~60℃ 정도가 적절한데, 고온으로 장시간 건조할 경우 포도당의 색이 변색되거나 포도당 분해물인 5-히드록시메틸플루랄(5-HMF)류가 생성될 소지가 있기 때문이다.The drying temperature of the granules prepared in the second step is about 30 ~ 60 ℃ is appropriate, when drying at high temperature for a long time discoloration of glucose or 5-hydroxymethylflural (5-HMF) which is a decomposition product of glucose This is because there is a possibility that is generated.
상기 pH 조정제는, 아세트산, 옥살산, 숙신산, 시트르산, 타르타르산, 말레인산을 포함하는 유기산, 및 염산을 포함하는 무기산으로 구성되는 군으로부터 선택되는 하나 이상인 것을 특징으로 하며, 바람직하게는 아세트산, 더욱 바람직하게는 99% 이상의 순도를 갖는 빙초산인 것을 특징으로 한다. 상기 pH 조정제는, 바인더 용액과 마찬가지로, 미세하게 분사할 수 있는 오리피스를 장착한 노즐을 이용하여 분사하여, 짧은 시간 내에 제조를 완료하여, pH 조정제의 휘발에 의한 pH의 변화를 유발하지 않으면서 균일하게 분포될 수 있도록 한다. The pH adjuster is at least one selected from the group consisting of acetic acid, oxalic acid, succinic acid, citric acid, tartaric acid, organic acid containing maleic acid, and hydrochloric acid, preferably acetic acid, more preferably It is characterized by glacial acetic acid having a purity of 99% or more. Like the binder solution, the pH adjuster is sprayed using a nozzle equipped with an orifice that can be finely sprayed to complete the preparation within a short time, without causing a pH change due to volatilization of the pH adjuster. To be distributed.
이때, 상기의 pH 조정제는 포도당의 안정성에 영향을 주지 않으면서, 본 발명의 투석용 고형 제제가 목표로 하는 적절한 산성 pH 범위인 pH 4.0~5.5로 제조하기 위해서, 상기 과립의 총 중량에 대하여 1.0~4.0 중량%의 함량이 되도록 분사될 수 있다. 상기 적절한 pH 범위인 pH 4.0~5.5의 범위로 제조된 본 발명의 고형 제제와 약염기성인 중탄산나트륨을 혼합하면, 산과 중탄산이 반응하여 CO2가 생성되고 탄산염이 석출되지 않으면서 최종 투석액의 pH가 7.0~7.4의 범위가 된다.At this time, the pH adjuster is 1.0 with respect to the total weight of the granules in order to produce a pH range of pH 4.0 ~ 5.5, which is an appropriate acidic pH range targeted by the dialysis solid preparation of the present invention without affecting the stability of glucose It may be sprayed to a content of ˜4.0% by weight. When the solid preparation of the present invention prepared in the appropriate pH range of pH 4.0 to 5.5 is mixed with the weakly basic sodium bicarbonate, the acid and bicarbonate react to produce CO 2 , and the pH of the final dialysate is 7.0 without precipitation of carbonate. It is in the range of ~ 7.4.
본 발명에 의한 제제는, 입도측정기(Mastersizer X, Malvern, UK)를 이용하여, 플로우 셀(Flow cell)에 상기 제제를 15g 투입한 후, 입자가 용해를 시작한 시점부터 입자가 완전히 녹아 사라지는 시간이 110초 이하이다. 이와 같은 제제의 특징은 본원 발명의 분무 건조물을 제조하는 제1 단계에서 분말입경이 20 ㎛ 내지 75 ㎛인 분무 건조물을 수득하고, 상기 제1 단계의 분무 건조물에 바인더 용액을 분사하여 과립 제조하고 이 과립에 pH 조정제를 분사하여 혼합함으로써, 20 내지 100 메쉬(약 850 ㎛ ~ 150 ㎛) 크기의 과립이 전체 제제 중 75%이상 수득되게 함으로써 달성 가능하다. 입경이 200 메쉬(약 75 ㎛) 미만인 경우, 입자끼리 뭉치는 경향이 나타나므로 용해도의 저하가 일어날 수 있고 유동성에도 부정적인 영향을 미치며, 비산(飛散)하는 등의 취급상의 문제가 나타난다. 입경이 18 메쉬(약 1,000 ㎛)를 초과하면 용해속도가 특히 늦어져서 바람직하지 않다. In the preparation according to the present invention, 15 g of the preparation is introduced into a flow cell using a particle size analyzer (Mastersizer X, Malvern, UK), and the time for the particles to dissolve completely disappears from the time when the particles start dissolving. 110 seconds or less. The characteristics of such a preparation is to obtain a spray dried product having a particle size of 20 μm to 75 μm in the first step of preparing the spray dried product of the present invention, and to prepare granules by spraying a binder solution on the spray dried material of the first step. By spraying and mixing the pH adjuster into the granules, it is achievable by allowing granules of 20 to 100 mesh (about 850 μm to 150 μm) to be obtained at least 75% of the total formulation. When the particle diameter is less than 200 mesh (about 75 μm), particles tend to aggregate, so that a decrease in solubility may occur, adversely affect the fluidity, and handling problems such as scattering may occur. If the particle diameter exceeds 18 mesh (about 1,000 mu m), the dissolution rate is particularly slow, which is not preferable.
본 발명에 의한 제제의 흡습도는 25 ℃, 60%의 상대습도 조건에서 18시간 방 치한 후 약 0.01~7.0%, 더욱 바람직하게는 약 0.1~5.0%가 적합하다. The hygroscopicity of the preparations according to the invention is about 0.01-7.0%, more preferably about 0.1-5.0% after being left for 18 hours at 25 ° C. and 60% relative humidity conditions.
본 발명에 의한 제제는, 안식각은 40° 이하이고 밀도는 0.6~1.0 g/ml가 적합하며, 보다 바람직하게는 안식각은 40° 이하이고 밀도는 0.7~0.85 g/ml이다. 이는 본원 발명의 분무건조물을 제조하는 제1 단계에서 20 ㎛ 내지 75 ㎛ 정도의 분말입경을 갖는 분무 건조물을 수득하고, 상기 제1 단계의 분무 건조물을 포함하는 대상물에 바인더 용액을 분사하여 과립 제조 후, 상기 과립에 pH 조정제를 분사하여 혼합하는 공정을 통하여 달성할 수 있다. 안식각이 40° 이하인 경우, 유동성이 좋아지므로, 제제를 취출할 때에 한번에 원하지 않는 대량의 제제가 투입되는 것을 방지할 수 있으며, 분말 포장 시 일반적으로 사용되는 무게 컨트롤 장치에 원활히 투입될 수 있어 취급상 유리하다. The formulation according to the present invention has an angle of repose of 40 ° or less and a density of 0.6-1.0 g / ml is suitable, more preferably an angle of repose of 40 ° or less and a density of 0.7-0.85 g / ml. This yields a spray dried product having a powder particle size of about 20 μm to 75 μm in the first step of preparing the spray dried product of the present invention, and after the preparation of granules by spraying a binder solution on the object including the spray dried product of the first step , By spraying a pH adjuster to the granules can be achieved through the process of mixing. When the angle of repose is 40 ° or less, the fluidity is improved, which prevents the introduction of a large amount of undesired formulations at a time when taking out the formulation, and can be smoothly added to a weight control device commonly used for powder packaging. It is advantageous.
상기와 같은 방법으로 제조된 본 발명의 투석용 제제는, 전해질 성분, pH 조정제 및 포도당의 조성이 하기 표 1에 나타낸 바와 같이 배합됨이 바람직하다. In the dialysis preparation of the present invention prepared by the above method, the composition of the electrolyte component, the pH adjuster and the glucose is preferably blended as shown in Table 1 below.
본 발명에서는 유동성을 개선함은 물론, 전해질 성분뿐만 아니라 추가되는 성분들의 균일성까지 확보하고, 특히 우수한 용해속도를 가지며, 낮은 흡습도를 갖는 투석용 고형 제제 및 이의 제조방법을 개시하였다.In the present invention, as well as improving the fluidity, as well as to ensure the uniformity of the electrolyte components as well as the additional components, and particularly has a good dissolution rate, has been disclosed a solid preparation for dialysis and a method for producing the same.
본 발명의 제조 방법으로 제조된 투석용 고형 제제는 분무 건조물을 과립화한 투석용제로서, 전해질 성분의 함량 균일성, 용해속도 및 유동성이 뛰어나므로 투석액 제조 시 균일한 함량의 액상으로 복원될 수 있다. 또한, 흡습성이 매우 낮아 상대 습도에 의해 민감하게 반응하지 않으므로 제조 시 및 보관 중에도 굳거나 응집에 의한 괴상물을 형성하지 않기 때문에 용해속도가 떨어지는 문제의 발생 소지가 매우 낮으며, 장기간 보존하더라도 상품성이 유지된다. The solid preparation for dialysis prepared by the preparation method of the present invention is a dialysis solvent obtained by granulating the sprayed dry matter, and thus the content uniformity, dissolution rate, and fluidity of the electrolyte components are excellent, and thus, the dialysis liquid may be restored to a uniform liquid phase. . In addition, the hygroscopicity is very low, so it does not react sensitively by relative humidity, so it does not form a solid or agglomerate due to agglomeration during manufacture and storage, so the problem of low dissolution rate is very low. maintain.
이하, 실시예 및 시험예를 들어 본 발명을 보다 구체적으로 설명하지만, 이들은 본 발명을 예시하기 위한 것이며, 이들에 의하여 본 발명의 범위가 한정되는 것은 아니다.Hereinafter, although an Example and a test example are given and this invention is demonstrated more concretely, these are for illustrating this invention, and the scope of the present invention is not limited by these.
실시예Example 1 One
염화나트륨 (Dominion, 뉴질랜드) 255.24 g, 염화칼륨(Merck, 독일) 6.264 g 아세트산나트륨(Verdugt, 스페인) 34.242 g, 염화칼슘(Merck, 독일) 9.264 g 및 염화마그네슘(Merck, 독일) 4.272 g을 물 886.62 g에 녹였다. 이 용액을 분무건조기(B-191, BUchi, Switzerland)에 투입하고 [표2]의 조건으로 분무건조시켜 분무건조물 200 g을 수득하였다. 상기 분무건조물 200 g와 포도당(Dextrose anhydrous, 삼양제넥스) 28.846 g을 조립기(FM-VG-01, POWREX, JAPAN)에 투입하고, chopper 2000rpm, blade 150rpm 조건으로 8분간 혼합하였다. 혼합하면서 단공형 오리피스 (직경 0.8 mm)를 갖는 노즐 분무기(air atomizer)를 이용하여, 바인더 용액인 증류수 15g을 분사하여 과립을 생성하였다. 생성된 과립을 50 ℃의 건조 오븐에서 6시간 건조시킨 후 20 메시(mesh) 체를 이용하여 정립하였다. 상기 정립된 과립을 조립기에 넣고, chopper 2000 rpm, blade 150 rpm 조건으로 가동하면서, 상기 노즐 분무기를 이용하여 아세트산 4.58 g을 혼합하여 고형 제제를 제조하였다. 상기의 과정을 하기 표 3에 나타내었다. 255.24 g of sodium chloride (Dominion, New Zealand), 6.264 g of potassium chloride (Merck, Germany) 34.242 g of sodium acetate (Verdugt, Spain), 9.264 g of calcium chloride (Merck, Germany) and 4.272 g of magnesium chloride (Merck, Germany) in 886.62 g of water Melted. The solution was poured into a spray dryer (B-191, BUchi, Switzerland) and spray dried under the conditions of [Table 2] to obtain 200 g of a spray dried product. 200 g of the spray dried product and 28.846 g of glucose (Dextrose anhydrous, Samyang Genex) were added to a granulator (FM-VG-01, POWREX, JAPAN) and mixed for 8 minutes under conditions of chopper 2000 rpm and blade 150 rpm. Granules were produced by spraying 15 g of distilled water, a binder solution, using a nozzle air atomizer with a single pore orifice (0.8 mm in diameter) while mixing. The resulting granules were dried in a drying oven at 50 ° C. for 6 hours and then sized using 20 mesh sieves. The granulated granules were placed in a granulator, and operated at chopper 2000 rpm and blade 150 rpm, and 4.58 g of acetic acid was mixed using the nozzle sprayer to prepare a solid formulation. The above process is shown in Table 3 below.
실시예Example 2 2
실시예 1의 제조 방법 중, 단공형 오리피스를 갖는 노즐 분무기 대신, 원형의 6공형 오리피스를 갖는 노즐 분무기를 이용하여 바인더 용액을 분사하는 것을 제외하고, 실시예 1과 동일한 조성 및 제조 방법을 이용하여 고형 제제를 제조하였다.Using the same composition and manufacturing method as in Example 1, except that the binder solution was sprayed using a nozzle sprayer having a round six-hole orifice instead of the nozzle sprayer having a single hole orifice. Solid formulations were prepared.
실시예Example 3 3
실시예 2의 제조 방법 중, 바인더 용액으로 40% 포도당 용액(포도당 10g + 증류수 15g)을 사용하고, 분무건조물에 혼합하는 포도당의 양이 18.846 g인 것을 제외하고, 실시예 1과 동일한 조성 및 제조 방법을 이용하여 고형 제제를 제조하였다.In the preparation method of Example 2, the same composition and preparation as in Example 1, except that 40% glucose solution (10 g of glucose + 15 g of distilled water) was used as the binder solution, and the amount of glucose mixed in the spray dried product was 18.846 g. Solid formulations were prepared using the method.
비교예Comparative example 1 One
염화나트륨 255.24 g, 염화칼륨 6.264 g 및 아세트산나트륨 34.242 g, 염화칼슘 9.264 g, 염화마그네슘 4.272 g, 포도당 42 g, 아세트산 4.58 g을 브이 믹서(V-mixer, Erweka, Germany)에 넣고 30분간 혼합하였다. Sodium chloride 255.24 g, potassium chloride 6.264 g and sodium acetate 34.242 g, calcium chloride 9.264 g, magnesium chloride 4.272 g, glucose 42 g, acetic acid 4.58 g were placed in a V-mixer (V-mixer, Erweka, Germany) and mixed for 30 minutes.
비교예Comparative example 2 2
염화나트륨 255.24 g, 염화칼륨 6.264 g 및 아세트산나트륨 34.242 g, 염화칼슘 9.264 g, 염화마그네슘 4.272 g, 포도당 42 g을 브이-믹서(V-mixer, Erweka, Germany)에 넣고 30분간 혼합한 후 건식조립기(TG-2000, Erweka, Germany)를 이용하여 조립하였다. 이 조립물을 피츠 밀(fitz-mill, Fitzpatrick, USA)로 분쇄한 후 아세트산 4.58 g을 8분간 관을 통하여 적하하며 혼합하였다.255.24 g of sodium chloride, 6.264 g of potassium chloride and 34.242 g of sodium acetate, 9.264 g of calcium chloride, 4.272 g of magnesium chloride, and 42 g of glucose were added to a V-mixer (V-mixer, Erweka, Germany) and mixed for 30 minutes, followed by a dry granulator (TG- 2000, Erweka, Germany). This assembly is called fitz-mill, Fitzpatrick, USA) and 4.58 g of acetic acid were added dropwise through a tube for 8 minutes to mix.
비교예Comparative example 3 3
제트 밀(Jet mill)을 이용하여 염화나트륨 255.24 g, 아세트산나트륨 34.242 g 및 염화칼슘 9.264 g, 염화마그네슘 4.272 g, 염화칼륨 6.264 g, 포도당 42 g을 분쇄하였다. 이를 조립기(FM-VG-01, powrec, Japan; Vertical granulator)에 투입하고, 아세트산 4.58 g을 관을 이용하여 적하하며 8분간 혼합하였다. A jet mill was used to grind 255.24 g of sodium chloride, 34.242 g of sodium acetate and 9.264 g of calcium chloride, 4.272 g of magnesium chloride, 6.264 g of potassium chloride, and 42 g of glucose. This was put into a granulator (FM-VG-01, powrec, Japan; Vertical granulator), and 4.58 g of acetic acid was added dropwise using a tube and mixed for 8 minutes.
비교예Comparative example 4 4
제트 밀(Jet mill)을 이용하여 염화나트륨 255.24 g, 아세트산나트륨 34.242 g 및 염화칼슘 9.264 g, 염화마그네슘 4.272 g, 염화칼륨 6.264 g, 포도당 42 g을 분쇄하고, 조립기(FM-VG-01, powrec, Japan; Vertical granulator)에 투입하여 혼합하면서 증류수 15g을 관을 통하여 적하하며 과립을 제조하였다. 아세트산은 4.58g 적하하며 8분간 혼합하였다. Using a jet mill, 255.24 g of sodium chloride, 34.242 g of sodium acetate and 9.264 g of calcium chloride, 4.272 g of magnesium chloride, 6.264 g of potassium chloride, and 42 g of glucose were ground and a granulator (FM-VG-01, powrec, Japan; 15g of distilled water was added dropwise through a tube while mixing into a vertical granulator to prepare granules. 4.58 g of acetic acid was added dropwise and mixed for 8 minutes.
비교예Comparative example 5 5
염화나트륨 255.24 g, 염화칼륨 6.264 g 및 아세트산나트륨 34.242 g, 염화칼슘 9.264 g, 염화마그네슘 4.272 g을 물 886.62 g에 녹인 후, 이 용액을 실시예 1과 같은 조건으로 분무건조하여 분무건조물 200g을 수득하였다. 255.24 g of sodium chloride, 6.264 g of potassium chloride and 34.242 g of sodium acetate, 9.264 g of calcium chloride, and 4.272 g of magnesium chloride were dissolved in 886.62 g of water, and the solution was spray dried under the same conditions as in Example 1 to obtain 200 g of a spray dried product.
시험예Test Example 1. 함량균일성 분석 1. Content Uniformity Analysis
상기 실시예 및 비교예로부터 랜덤하게 시료를 7개 샘플링 하여 각각의 시료를 이온크로마토 그래피 (기기: Metrohm 761 Compact IC, Metrohm 813 Compact Autosampler, Metrohm 753 Suppressor Module, 양이온 column: Metrohm C2 100, 음이온 column: Mertohm A Supp5 100*4mm, Switzerland)에 적용하여 이온의 농도를 측정하여 하기 표 4에 나타내었다. Seven samples were randomly sampled from the above examples and comparative examples, and each sample was subjected to ion chromatography (device: Metrohm 761 Compact IC, Metrohm 813 Compact Autosampler, Metrohm 753 Suppressor Module, cation column: Metrohm C2 100, anion column: Mertohm A Supp5 100 * 4mm, Switzerland) to measure the concentration of ions are shown in Table 4 below.
양이온(K, Ca, Mg, Na) 표준 샘플링 조건은 하기와 같았다. 분석하고자 하는 상기 양이온의 농도 확인을 위해, 염화칼륨(Potassium chloride), 염화칼슘(Calcium chloride), 염화마그네슘(Magnesium chloride), 염화나트륨(Sodium chloride)을 부피 플라스크(volumetric flask)에 넣고 물에 녹여 소정 농도의 표준 용액을 3~5 포인트 제조하고, 실험을 통해 얻어진 값을 이용하여 교정 곡선(calibration curve)를 이용해 샘플의 농도를 구하였다. Cation (K, Ca, Mg, Na) standard sampling conditions were as follows. To confirm the concentration of the cation to be analyzed, potassium chloride (Potassium chloride), calcium chloride (Calcium chloride), magnesium chloride (Magnesium chloride), sodium chloride (Sodium chloride) is put in a volumetric flask (volumetric flask) and dissolved in water of a predetermined concentration A standard solution was prepared for 3 to 5 points, and the concentration of the sample was determined using a calibration curve using the values obtained through the experiment.
음이온(Cl,Acetate) 표준 샘플링 조건은 하기와 같았다. 분석하고자 하는 상기 양이온의 농도 확인을 위해, 염화나트륨(Sodium chloride) 및 아세트산(Acetic acid)을 부피 플라스크(volumetric flask)에 넣고 물에 녹여 소정 농도의 표준 용액을 3~5 포인트 제조하고, 실험을 통해 얻어진 값을 이용하여 교정 곡선(calibration curve)를 이용해 샘플의 농도를 구하였다. 또한, 각 시료의 비선광도를 측정하여 포도당 함량 및 표준편차를 확인하여 하기 표 4에 나타내었다.Anion (Cl, Acetate) standard sampling conditions were as follows. In order to confirm the concentration of the cation to be analyzed, sodium chloride and acetic acid were added to a volumetric flask and dissolved in water to prepare 3 to 5 points of a standard solution having a predetermined concentration. Using the obtained values, the concentration of the sample was determined by using a calibration curve. In addition, by measuring the specific light intensity of each sample to determine the glucose content and the standard deviation is shown in Table 4 below.
표 4의 결과에 나타난 바와 같이, 실시예의 이온농도가 비교예의 이온농도에 비해 균일한 것으로 나타나, 분쇄하거나 분쇄하지 않은 전해질의 단순 혼합 및/또는 조립물, 및 전해질의 분무건조물인 비교예에 비해, 본 발명의 실시예는 우수한 함량균일성을 달성하는 투석용제를 제공할 수 있음을 확인할 수 있다. As shown in the results of Table 4, the ion concentration of the example was shown to be uniform compared to the ion concentration of the comparative example, compared to the comparative example of a simple mixture and / or granulated material of the pulverized or unpulverized electrolyte, and the spray dried of the electrolyte. , Examples of the present invention can be seen that it can provide a dialysis solvent to achieve excellent content uniformity.
시험예Test Example 2. 2. 안식각Repose 및 밀도 측정 And density measurement
유동성 확인을 위하여 안식각 측정기(GTB, Erweka, Germany)를 이용하여 안식각(흐름각)을 측정하였으며, 밀도는 밀도 측정기(SVM202, Erweka, Germany)를 이용하여 USP Method 1으로 측정하여 하기 표 5에 나타내었다.In order to check the fluidity, the angle of repose (flow angle) was measured by using an angle measuring device (GTB, Erweka, Germany), and the density was measured by USP Method 1 using a density measuring device (SVM202, Erweka, Germany). It was.
통상적으로 고형제의 경우에 안식각이 40°이하인 경우에 유동성이 양호하다고 판단하게 되며, 표5에 나타난 바와 같이, 실시예의 경우에 모두 안식각이 40°이하의 것으로 나타났다. 안식각이 작을수록 과립의 흐름성이 우수한 것이다. 또한 비교예5의 분무건조물의 경우엔, 밀도가 0.34 g/ml로서, 액상투석제의 단점인 부피의 증가로 인한 물류나 보관 등의 문제를 개선하고자 하는 고형 투석제의 장점이 적어지게 되는데, 실시예의 경우엔 밀도가 비교예 5에 비하여 2배 이상(즉 0.79~0.83g/ml)을 나타낸다.Typically, in the case of a solid agent, when the angle of repose is 40 ° or less, it is determined that the fluidity is good, and as shown in Table 5, the angle of repose was less than 40 ° in all of the examples. The smaller the angle of repose, the better the flowability of the granules. In addition, in the case of the spray drying of Comparative Example 5, the density is 0.34 g / ml, the solid dialysis agent to reduce problems such as logistics or storage due to the increase in volume, which is a disadvantage of the liquid dialysis agent is less, In the case of the Example, a density is 2 times or more (that is, 0.79-0.83 g / ml) compared with the comparative example 5.
한편, 전해질 성분을 그대로 혼합하여 밀링한 경우인 비교예 1 내지 3은 밀도가 비교적 양호하더라도, 안식각이 불량한 것으로 나타났다. On the other hand, Comparative Examples 1 to 3, in which the electrolyte components were mixed and milled as they were, were found to have a poor angle of repose, even though the density was relatively good.
시험예Test Example 3. 입도 분포 측정 3. Measurement of particle size distribution
실시예 및 비교예를 체분석기(Sieve analysis VT, Erweka, Germany)에 적용하고, 여러 크기의 표준체를 기기에 설치한 후 200 rpm에서 10분간 작동시킨 후 각 체에 잔류한 분체의 무게를 칭량하여 환산한 입도 분포 결과를 하기 표 6에 나타내었다. Examples and comparative examples were applied to a sieve analysis (Sieve analysis VT, Erweka, Germany), and after the standard size of the various sizes were installed in the instrument and operated for 10 minutes at 200 rpm and weighed the weight of the powder remaining in each sieve Conversion particle size distribution results are shown in Table 6 below.
표 6의 결과에 나타난 바와 같이, 실시예의 경우에서, 미세분말의 형성이 억제되며 우수한 용해속도를 갖는 20~100 메시 크기(mesh size)의 과립의 비율이 75%이상으로 높게 나타났다.As shown in the results of Table 6, in the case of the Example, the formation of fine powder was suppressed and the ratio of the granules of 20-100 mesh size having an excellent dissolution rate was higher than 75%.
시험예Test Example 4. 용해속도 측정 4. Melt rate measurement
실시예와 비교예의 용해 속도를 다음의 방법에 의해 측정하였다. 용해 속도는 입도측정기(Mastersizer X, Malvern, UK)를 이용하여, 플로우 셀 (Flow cell)에 투석용제를 15 g 투입한 후, 제제의 입자가 용해를 시작한 시점부터 입자가 완전히 녹아 사라지는 시점을 측정하여 하기 표 7에 나타내었다. The dissolution rate of an Example and a comparative example was measured by the following method. The dissolution rate was measured using a particle size analyzer (Mastersizer X, Malvern, UK), after 15 g of a dialysis solvent was added to the flow cell, and then the time point at which the particles completely dissolved and disappeared from the time when the particles of the formulation began to dissolve. It is shown in Table 7 below.
표 7에 나타난 바와 같이, 비교예에 비해 실시예의 용해속도가 우수하였음을 알 수 있다. As shown in Table 7, it can be seen that the dissolution rate of the Example was superior to the comparative example.
시험예Test Example 5. 5. 흡습도Hygroscopicity 측정 Measure
실시예 3, 비교예3 및 4 를 25℃의 건조데시케이터 내에서 24시간 동안 충분히 건조시킨 후, 각각을 5g씩 페트리디쉬에 얇게 펼쳐 놓고 25℃, 60% 상대습도 조건에서 18 시간 방치한 후 시험 전후의 수분함량을 칼피셔 측정기(Karl Fischer moisture analyzer, Metrohm, Switzerland)를 이용하여 측정하여 하기의 표 8에 나타내었다. Example 3, Comparative Examples 3 and 4 were sufficiently dried in a drying desiccator at 25 ° C. for 24 hours, and each was spread out thinly in Petri dishes at 5 g and left for 18 hours at 25 ° C. and 60% relative humidity. The water content before and after the test was measured using a Karl Fischer moisture analyzer (Metrohm, Switzerland) and is shown in Table 8 below.
표 8에 나타난 바와 같이, 염을 분쇄하여 과립화 한 제제인 비교예 3 및 4에 비해, 분무건조물을 과립화한 제제인 실시예 3의 흡습도가 낮은 것으로 나타났다. 따라서, 본 발명의 제제인 실시예 3은 굳거나 응집에 의해 발생하는 괴상물의 형성 가능성이 낮은 것으로 나타났다.As shown in Table 8, compared with Comparative Examples 3 and 4, which are granulated salts, the hygroscopicity of Example 3, which was a granulated spray dried product, was low. Thus, Example 3, which is a formulation of the present invention, was found to have a low likelihood of formation of masses caused by solidification or aggregation.
Claims (13)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070135594A KR20090067809A (en) | 2007-12-21 | 2007-12-21 | Solid preparation for dialysis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020070135594A KR20090067809A (en) | 2007-12-21 | 2007-12-21 | Solid preparation for dialysis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090067809A true KR20090067809A (en) | 2009-06-25 |
Family
ID=40995483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020070135594A Withdrawn KR20090067809A (en) | 2007-12-21 | 2007-12-21 | Solid preparation for dialysis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20090067809A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140046374A (en) * | 2012-10-10 | 2014-04-18 | 도미따 세이야꾸 가부시끼가이샤 | A dialysis agent a containing acetic acid and acetate salt, and a two-part dialysis agent using thereof |
-
2007
- 2007-12-21 KR KR1020070135594A patent/KR20090067809A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140046374A (en) * | 2012-10-10 | 2014-04-18 | 도미따 세이야꾸 가부시끼가이샤 | A dialysis agent a containing acetic acid and acetate salt, and a two-part dialysis agent using thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5258268B2 (en) | Method for producing spherical particles | |
| CN108472261B (en) | Apixaban solid composition and preparation method thereof | |
| JP2012504580A (en) | Inhalable particles containing tiotropium | |
| CN110354086B (en) | Preparation method of candesartan cilexetil tablets | |
| CN118680914B (en) | Bumetanide composition and preparation method thereof | |
| CN105878202A (en) | Tofacitinib citrate tablet and preparation method thereof | |
| CN101631549B (en) | Process for production of buprenorphine pharmaceutical preparation to be applied to mouth mucosa | |
| JP3368898B1 (en) | Process for producing granules containing branched chain amino acids | |
| US20110189295A1 (en) | Telmisartan tablets | |
| CN106943367B (en) | Afatinib maleate tablet and preparation method thereof | |
| KR20090067809A (en) | Solid preparation for dialysis and preparation method thereof | |
| CN104997744A (en) | A kind of high stability capecitabine tablet and preparation method thereof | |
| CN113599366A (en) | A kind of tenofovir disoproxil fumarate particles and preparation method thereof | |
| CN113575922A (en) | Phosphate additive and preparation method thereof | |
| CN112516095A (en) | Ezetimibe tablets and preparation method thereof | |
| JPH031288B2 (en) | ||
| CN106265557A (en) | Pharmaceutical composition containing ticagrelor | |
| CN106420651B (en) | A kind of preparation method of Apixaban tablet | |
| CN106389428B (en) | A composition with improved bioavailability and stability of azilsartan and its preparation method | |
| CN104644601B (en) | Capecitabine tablet | |
| CN116889551A (en) | A kind of compound sodium picosulfate granules with high content uniformity and preparation method thereof | |
| JP4997741B2 (en) | Low melting point drug-containing powder and method for producing the same | |
| CN113769059A (en) | A kind of polyprene zinc granules and preparation method thereof | |
| CN103110590B (en) | Cymipristone solid preparation and preparation method thereof | |
| EP2915526A1 (en) | Pharmaceutical compositions comprising anagrelide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20071221 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |